A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants
A Bioequivalence Study of Subcutaneous Injections of Mirikizumab Reference Solution Using an Investigational 1-mL Autoinjector and Mirikizumab Test Solution Formulation Using an Investigational 1-mL Autoinjector in Healthy Participants
Sponsor: Eli Lilly and Company
Listed as NCT05515601, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Eli Lilly and Company, it has been updated 6 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE1
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Dec 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 1 earlier version
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE1
First recorded
Aug 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .